PELLIZZARI, GLORIA
PELLIZZARI, GLORIA
Universita' degli Studi di MILANO
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
2024 C. Valenza, M. Mongillo, F. Gigli, D. Trapani, J. Katrini, E. Nicolò, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, S. Derio, M. Lapresa, G. Parma, E. Derenzini, G. Curigliano, N. Colombo
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
2024 C. Belli, L. Boscolo Bielo, M. Repetto, E. Crimini, R. Scalia, A. Diana, J. Orefice, L. Ascione, G. Pellizzari, N. Fusco, M. Barberis, B. Daniele, E. Guerini-Rocco, G. Curigliano
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
2024 L. Boscolo Bielo, C. Belli, E. Crimini, M. Repetto, L. Ascione, G. Pellizzari, C. Santoro, V. Fuorivia, M. Barberis, N. Fusco, E.G. Rocco, G. Curigliano
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study
2024 D. Trapani, R. Scalia, E. Giordano, G. Castellano, G. Doi, A. Gaeta, G. Pellizzari, A. Carnevale Schianca, J. Katrini, S. D'Ambrosio, C. Santoro, L. Guidi, C. Valenza, C. Belli, S. Gandini, A. Russo, G. Curigliano
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
2023 L. Guidi, G. Pellizzari, P. Tarantino, C. Valenza, G. Curigliano